When CAMR was developed and reviewed by Parliament, there was testimony by several pharmaceutical manufacturing companies that the duration of the average pharmaceutical supply contract was two years, so that was taken into consideration.
There was also the interest in making sure that importing countries that chose to use the decision to receive drugs wouldn't be tied to an indefinite contract. They could go out and seek the best price in the marketplace at that time and there wouldn't an unlimited duration of a contract under CAMR.